Results 191 to 200 of about 11,001,215 (252)

Efficacy and safety of pharmacological interventions for the treatment of cocaine use disorder: A systematic review and network meta‐analysis

Addiction, Volume 121, Issue 11, Page 2897-2958, November 2026.
Abstract Background and aims Cocaine use disorder (CUD) is an increasingly widespread concern worldwide. Various pharmacological treatments have been investigated for CUD, but their efficacy remains unclear, and none have been licensed for treatment.
Craig Paterson, Thomas Parkhouse, Chloe Burke, Monika Halicka, Jennifer C. Palmer, Hend Gabr, Rebecca Wilson, Katie E. Webster, Francesca Spiga, Sarah Dawson, Deborah M. Caldwell, Jennifer Scott, Julian P. T. Higgins, Jelena Savović   +13 more
wiley   +1 more source

Craving and personal functioning as mediators of extended‐release buprenorphine efficacy: A four‐way decomposition analysis from a randomised trial

Addiction, Volume 121, Issue 11, Page 3010-3024, November 2026.
Abstract Aims To investigate whether the treatment effect of extended‐release buprenorphine (BUP‐XR) on opioid‐free days in opioid use disorder (OUD) is mediated by reductions in opioid craving and improvements in personal functioning. Design and setting Exploratory causal mediation analysis using VanderWeele's four‐way decomposition framework in a 24 ...
John Marsden, Mike Kelleher, Fiona Cowden, Edward Day, Jonathan Dewhurst, Rachel Evans, Eilish Gilvarry, Natalie Lowry, Luke Mitcheson, Robert Murray, Sophie Quarshie, Zoë Hoare   +11 more
wiley   +1 more source

Overdose reversal through peer intervention: Findings from the naloxone prospective outcome research study (NalPORS) on the effectiveness of overdose response by people who use opioids in the United Kingdom and Sweden

Addiction, Volume 121, Issue 11, Page 3025-3039, November 2026.
Abstract Background/aims Take‐home naloxone (THN) programmes have been introduced in many European countries to provide non‐medically trained people who are likely to witness an opioid overdose, including people who use opioids, with a naloxone kit and training.
Nicola Metrebian, Teodora Dascal, Clare Mackie, Rose Tinch‐Taylor, Ben Carter, Joanne Neale, Mariana Gonzalez Utrilla, Ed Day, Joar Guterstam, Kirsten Horsburgh, Martin Kåberg, Mike Kelleher, Soraya Mayet, Josie Smith, Desiree Eide, Elin Holmén, Rebecca McDonald, Stephen Parkin, Henrik Thiesen, John Strang, NalPORS Research Team, Dean Acreman, Shabana Akhtar, Louise Aitken, Martin Anderson, James Cassidy, Sarah Cosgrove, Jo Grayer, Michelle Hughes, Louise Horn, Anika Miah, John Pratt   +31 more
wiley   +1 more source

Clinical applications of wearable devices for individuals with at‐risk substance use and substance use disorders: A systematic review

The American Journal on Addictions, Volume 35, Issue 6, Page 702-726, November 2026.
Abstract Background and Objectives Managing substance use disorders (SUDs) is limited by the lack of longitudinal clinical data during active use and recovery. Wearable devices may help address this gap by capturing physiological and behavioral data in real‐world settings.
Alexandra Sas, Matthew E. Sloan, Yaoyi Xing, Ethan Kim, Dhvani Mehta, Anna Mouzenian, Lena C. Quilty, Jeffrey D. Wardell, Shannon Lange, Daniel Felsky, Victor M. Tang   +10 more
wiley   +1 more source

Spotlight commentary: Addressing the persistent problem of benzodiazepine overuse, time for clinical, educational and AI‐driven reform

British Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3703-3706, November 2026.
Jakša Vukojević, Luka Horvat, Vito Papić, Andrija Štajduhar   +3 more
wiley   +1 more source

Opioid withdrawal syndrome‐associated cognitive impairment: A narrative review

The American Journal on Addictions, Volume 35, Issue 6, Page 661-672, November 2026.
Abstract Background and Objectives Opioid withdrawal syndrome (OWS) comprises a transient constellation of subjective symptoms and objective signs expressed by brain and other organs. Although cognitive impairment is well documented in opioid use and addiction, little is known about cognitive impairment that may specifically accompany OWS.
Faizan Khan, Nazli Tunali, R. Andrew Chambers   +2 more
wiley   +1 more source

Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 9, Page 1219-1233, November 2026.
Summary of a multicentre TriNetX study evaluating outcomes after percutaneous coronary intervention (PCI) in patients with cirrhosis. Cirrhosis was associated with higher 1‐year gastrointestinal bleeding and mortality, especially with decompensated disease.
Dhir Gala, Sameer Rao, Manas Gunani, Kajol Shah, Anand V. Kulkarni, Karn Wijarnpreecha, Daniel Q. Huang, Pojsakorn Danpanichkul, Ahmed Al‐Khazraji, Kaveh Hajifathalian, Vivek Lingiah, Paul Gaglio, Nikki Duong, Christine Gerula   +13 more
wiley   +1 more source

Covalent fluorescent probes for 2‐arachidonoylglycerol metabolic pathways

British Journal of Pharmacology, Volume 183, Issue 22, Page 6656-6662, November 2026.
Abstract Covalent fluorescent probes have emerged as versatile chemical tools to visualise active enzymes in complex biological systems. When tailored for specific applications, ranging from activity‐based protein profiling for drug development to high spatiotemporal resolution imaging of enzymatic activities, these probes provide unique insights into ...
Nick D. F. Puijmbroeck, Mario van der Stelt   +1 more
wiley   +1 more source

The Impact of Heterogeneity in Individual Characteristics and Motivation to Quit Heroin Use on Contingency Management and Opioid Agonist Treatment Response: A Latent Class Analysis

Drug and Alcohol Review, Volume 45, Issue 7, November 2026.
ABSTRACT Introduction Contingency Management (CM) involves the systematic application of positive reinforcement (financial incentives) to promote behaviour change, to improve treatment outcomes for individuals with opioid use disorder (OUD). To better understand patient heterogeneity, this study sought to identify meaningful subgroups/classes ...
Louise MacGregor, Timothy Weaver, John Strang, Stephen Pilling, Nicola Metrebian, Kimberley Goldsmith   +5 more
wiley   +1 more source

Evaluating Harm Reduction Advice From Large Language Models

Drug and Alcohol Review, Volume 45, Issue 7, November 2026.
ABSTRACT Introduction Large language models (LLM) and generative Artificial Intelligence are increasingly providing health information. We have applied a novel method to evaluate the harm reduction information generated by popular LLMs. We focused on the filtration of oral medications for injection and the availability of local harm reduction services.
Khy Choo, Nathan Smith, Bernadette Ward, Robert M. Lundin   +3 more
wiley   +1 more source